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Abstract
Objective—Chemokines are known to play an important role in the pathophysiology of alcoholic
hepatitis (AH), a form of acute-on-chronic liver injury frequently mediated by gut derived
lipopolysaccharide (LPS). In our study, we hypothesise that chemokine CCL20, one of the most
upregulated chemokines in patients with AH, is implicated in the pathogenesis of AH by
mediating LPS induced liver injury.
Design—CCL20 gene expression and serum levels and their correlation with disease severity
were assessed in patients with AH. Cellular sources of CCL20 and its biological effects were
evaluated in vitro and in vivo in chronic, acute and acute-on-chronic experimental models of
carbon tetrachloride and LPS induced liver injury. RNA interference technology was used to
knockdown CCL20 in vivo.
Results—CCL20 hepatic and serum levels were increased in patients with AH and correlated
with the degree of fibrosis, portal hypertension, endotoxaemia, disease severity scores and short
term mortality. Moreover, CCL20 expression was increased in animal models of liver injury and
particularly under acute-on-chronic conditions. Macrophages and hepatic stellate cells (HSCs)
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were identified as the main CCL20 producing cell types. Silencing CCL20 in vivo reduced LPS
induced aspartate aminotransferase and lactate dehydrogenase serum levels and hepatic
proinflammatory and profibrogenic genes. CCL20 induced proinflammatory and profibrogenic
effects in cultured primary HSCs.
Conclusions—Our results suggest that CCL20 upregulation is strongly associated with LPS and
may not only represent a new potential biomarker to predict outcome in patients with AH but also
an important mediator linking hepatic inflammation, injury and fibrosis in AH.
INTRODUCTION
Alcoholic liver disease (ALD) is a major cause of end stage liver disease worldwide and
includes a broad spectrum of disorders, from fatty liver and hepatic inflammation to more
severe forms of liver injury, including alcoholic hepatitis (AH), cirrhosis and hepatocellular
carcinoma.1 AH is the most severe form of ALD and leads to severe complications related to
liver failure, portal hypertension or bacterial infection, and is associated with high short term
mortality.1–4 AH episodes are associated with an important inflammatory response and a
rapid progression of liver fibrosis.5 Unfortunately, corticosteroid treatment is only effective
for a subset of patients,6 and no other efficient therapies are currently available. The
development of new therapeutic strategies in AH have been hampered by poor knowledge of
the molecular mechanisms157 and lack of animal models of severe AH, as the available
models do not reproduce all of the key histological features found in humans.58 However,
new animal models reproducing some of the features of AH in humans have been described
recently910 and will represent new important tools to study the disease.
Alcohol consumption induces disruption of the intestinal barrier and causes enhanced gut
permeability with subsequent translocation of bacterial derived lipopolysaccharide (LPS),
which leads to elevated serum levels of LPS in patients with AH.11–13 Once it reaches the
liver, LPS stimulates innate immune receptors, namely toll-like receptors (TLRs), mostly
expressed on Kupffer cells and hepatic stellate cells (HSCs).14 LPS mediated activation of
Kupffer cells is a crucial step for both liver inflammation and fibrogenesis by promoting
hepatocyte damage, increased leucocyte infiltration, and secretion of reactive oxygen
species and proinflammatory and profibrogenic cytokines.1516 Furthermore, LPS can also
directly contribute to HSC activation and promote liver fibrosis.1517 A previous translational
study from our laboratory using liver samples from patients with AH allowed us to identify
several deregulated pathways potentially implicated in the pathogenesis of AH, including a
cytokine–cytokine receptor interaction pathway.818 In the same study, we identified CCL20
as the most upregulated chemokine in patients with AH.
Chemokines are a family of small cytokines which have the properties of both chemotactic
mediators and cytokines.19 Chemokines mediate the infiltration of immune cells into the
injured liver but can also directly interact with hepatic resident cells during inflammation
and fibrosis.20 CCL20 was originally identified in the liver as a liver related and activation
related chemokine, and is also known as a macrophage inflammatory protein (MIP-3α).21
CCL20 has been described as the only chemokine interacting and activating CC chemokine
receptor 6 (CCR6), a receptor shared only with the antimicrobial β-defensins.22 CCL20 has
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been shown to be expressed in a broad spectrum of cells and tissue types. Based on the
variety of CCL20 inducing agents (LPS, tumour necrosis factor α (TNFα), interleukin
(IL)-1β), CCL20 and CCR6 have been described as being involved in both normal and
pathological processes,22 including chronic liver injury2324 and hepatocellular carcinoma.25
However, the role of CCL20 in chronic liver diseases and in the context of an acute-on-
chronic liver injury is not known.
In the present translational study, we investigated the potential role of CCL20 as a mediator
of LPS induced liver injury in AH. We performed an extensive study in liver samples from
well characterised patients with AH, and we demonstrated that CCL20 is upregulated in
these patients and correlates with grade of fibrosis, portal hypertension, endotoxaemia,
disease severity and mortality. Moreover, as there are no available experimental models of
AH, we explored the CCL20 cell sources and functions in experimental models of acute,
chronic and acute-on-chronic liver injury induced by LPS, carbon tetra-chloride (CCl4) and
their combination to reproduce some of the features of AH.
MATERIALS AND METHODS
Patients
Patients admitted to the Liver Unit, Hospital Clínic of Barcelona, with clinical, analytical
and histological features of AH from July 2009 to January 2012 were prospectively included
in the study. All patients included in this study gave informed consent and the protocol
conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved
by the ethics committee of the Hospital Clinic of Barcelona. CCL20 and LPS serum levels
were assessed in 49 patients, and hepatic gene expression analysis was performed in 32 liver
samples obtained by transjugular biopsy. Inclusion criteria for AH were: excessive alcohol
consumption (>60 g/day) prior to admission, elevated levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase and bilirubin, and
histological diagnosis of AH.226 Patients with hepatocellular carcinoma or any other
potential cause of liver disease were excluded from the study. All patients received
nutritional as well as psychological support in achieving alcohol abstinence. Fragments of
normal livers were selected as previously described.8 We included patients with HCV
induced liver disease (genotype 1) who did not use any previous antiviral therapy, patients
with compensated cirrhosis due to HCV or past history of alcohol abuse (abstinence for at
least 6 months), and a cohort of patients with morbid obesity and associated non-alcoholic
steatohepatitis according to Kleiner’s criteria. Clinical and histological characteristics of
these patients have been previously described.78
Determination of LPS and CCL20 serum levels in patients with AH
Serum samples were obtained from peripheral blood and stored at −80°C. LPS serum levels
were determined using the limulus amoebocyte lysate QCL-1000 test (Lonza Walkersville
Inc, Walkersville, Maryland, USA). CCL20 serum levels were measured in patients with
AH (n=49), HCV (n=8) and compensated alcoholic cirrhosis (n=15), and in healthy
volunteers (n=8), using the Quantikine Human CCL20/MIP-3α Immunoassay Kit (R&D
Systems, Minneapolis, Minnesota, USA).
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Cell cultures and in vitro assays
Human HSCs were isolated and cultured as previously described.7 To study CCL20
production and biological effects, HSCs were serum starved for 12 h and then incubated
with LPS 1 μg/mL (Sigma-Aldrich, St Louis, Missouri, USA), TNFα 1 ng/mL (R&D
Systems) and IL-1β 20 ng/mL (Sigma-Aldrich) for 24 h and with CCL20 250 ng/mL and 1
μg/mL (R&D Systems) for 24 h and 48 h, respectively. HSC migration assays were
performed using a Boyden chamber, and CCL20 induced extracellular signal regulated
kinase (ERK) activation was verified by western blotting (see online supplementary
material). RAW264 murine macrophages were incubated with LPS (10 ng/mL, 100 ng/mL
and 1 μg/mL) for 24 h, as previously described.7 RNA isolation and PCR analysis were
performed as described in the online supplementary material section.
Small hairpin interference inducing constructs
We first tested in RAW264 cells three small interfering RNAs (siRNAs) specific for both
isophorm 1 and 2 of CCL20 (s73425, s73427 and s73426; Ambion In Vivo siRNA, Ambion,
Life Technologies Corporation, Carlsbad, California, USA) (data not shown), and using
positive (Ambion In Vivo GAPDH Positive control siRNA, Ambion) and negative (Ambion
In Vivo Negative Control #1 siRNA, Ambion) controls. We chose the siRNA that best
inhibited Ccl20 gene expression for the production of CCL20 short hairpin interference
inducing construct (shRNA). Starting from the siRNA sequence, shRNAs for in vivo use
were constructed and provided by the Gene Silencing Platform at CIC bioGUNE (Bilbao,
Spain). Briefly, chemically synthesised oligonucleotides, including the gene target sequence
(or a scrambled sequence in the case of the control shRNA), and a 19 nt loop from human
miR30 were cloned into the pSM2C vector.
Mouse models of liver injury
Animal procedures were approved by the ethics committee of the University of Barcelona
and were conducted in accordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and by the Columbia University Institutional Animal Care
and Use Committee, and are in accordance with those set by the National Institutes of
Health.
Mice aged 8–10 weeks were administrated CCl4 and ethanol or LPS. To mimic the effects of
endotoxaemia in the context of chronic liver disease, we also used a model of acute-on-
chronic liver injury by combining the effects of chronic CCl4 with LPS. Different hepatic
cell populations were isolated from the livers of mice treated with CCl4 and LPS, and Ccl20
hepatic expression was evaluated. The effects of CCL20 were studied in vivo by injecting
mice with control shRNA or shRNA specific for CCL20 and LPS. The effects of shRNA on
hepatic inflammatory cell infiltration, and gene and protein expression were assessed by
quantitative PCR, immunohistochemistry and western blotting, respectively. For details on
methodology, please see the online supplementary material.
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Continuous variables are described as mean (95% CI) or median (IQR). Categorical
variables are described by means of counts and percentages. Comparisons between groups
were performed using the Student’s t test or the Mann–Whitney U test when appropriate.
Correlations between variables were evaluated using Spearman’s r or Pearson’s r, when
appropriate. The area under the receiver characteristic curve (AUROC) analysis was used to
determine the best cut-off value and the accuracy (sensitivity and specificity) of continuous
variables associated with 90 day mortality. Finally, we performed a survival analysis using
the Kaplan–Meier method. Comparisons were performed by the log rank test. All statistical
analyses were performed using SPSS V.14.0 for Windows (SPSS Inc, Chicago, Illinois,
USA).
RESULTS
General characteristics of patients with AH
Forty-nine patients were included in the study with clinical, analytical and histological
characteristics of AH. Seventy-eight per cent (n=38) of patients had severe AH at admission,
as defined as a ABIC (Age-Bilirubin-INR-Creatinine) score >6.71.2 Patients were
predominantly male (80%), and mean age was 52 years. Overall 90 day mortality was 29%.
The main causes of death were multiple organ dysfunction (65%) and severe sepsis (20%).
The main epidemiological, clinical, haemodynamic and analytical characteristics of the
patients are shown in table 1.
Patients with AH show increased CCL20 hepatic expression and serum levels
We previously identified CCL20 as the most upregulated CC chemokine in patients with
AH.8 To confirm this previous result, we analysed by real time PCR hepatic CCL20
expression in a cohort of patients with AH. The results confirmed marked upregulation of
CCL20 in patients with AH (n=32) compared with normal liver (n=8) (p<0.001) and other
liver diseases (p<0.001). CCL20 expression was also upregulated, but at a lower extent, in
patients with non-alcoholic steatohepatitis (n=8) (p<0.005), chronic hepatitis C (n=8)
(p<0.005) and compensated cirrhosis (n=8) (p<0.001) compared with control liver samples
(n=8) (figure 1A).
We next assessed CCL20 serum levels in patients with AH and other liver diseases. We
found that CCL20 serum levels were increased in patients with AH (n=49) (p<0.001), HCV
(n=8) and compensated alcoholic cirrhosis (n=15) (p<0.005) compared with healthy controls
(n=8). Of note, CCL20 circulating levels were higher in patients with AH compared with
patients with other liver diseases (p<0.001, figure 1B). Finally, we observed that hepatic
CCL20 mRNA expression and serum levels positively correlated in patients with AH (n=32)
(p=0.03, figure 1C), suggesting that the liver may be an important source of CCL20 in these
patients.
CCL20 expression correlates with disease severity and key features of AH
To gain insight into the pathogenic role of CCL20 in AH, we next explored whether its
expression correlated with disease severity. CCL20 hepatic expression positively correlated
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with important prognostic scores in patients with AH. Hepatic CCL20 correlated with
MELD (Model for End-stage Liver Disease) (p<0.0001) (figure 2A), ABIC (p=0.06) and
Maddrey’s (p=0.005) (see online supplementary figure S1A, B) scores. Moreover, we
observed higher levels of hepatic CCL20 expression in patients with severe AH compared
with those with mild to moderate grades of fibrosis and portal hypertension (54 vs 7-fold
expression (p=0.01) and 148 vs 34-fold expression (p=0.008), respectively) (figure 2B, C).
We next sought to investigate the correlation between circulating CCL20 and LPS, one of
the major inducers of CCL20. We observed that CCL20 and LPS serum levels were strongly
correlated (p<0.0001, figure 2D) in patients with AH. We also evaluated in our cohort of
patients hepatic infiltration of neutrophils (as described in the online supplementary material
section), an important hallmark in AH. We found that patients with higher levels of
circulating CCL20 showed severe hepatic infiltration of polymorphonuclear cells compared
with those with a mild grade of polymorphonuclear cell infiltration (p=0.007, see online
supplementary figure S1C).
Importantly, we observed increased hepatic CCL20 mRNA and serum levels in patients who
died within 90 days after admission compared with those who survived (160-fold vs 50-fold
induction (p=0.03) and 359 vs 168 pg/mL (p=0.048) respectively) (see online supplementary
figure S1D, E). In addition, to determine if CCL20 could be a good predictor of short term
mortality, a Kaplan–Meier analysis was performed. As shown in figure 2E and figure 2F,
CCL20 hepatic gene expression (receiver operating curve cut-off value of 80-fold (2−ΔΔCt),
AUROC 0.72, 95% CI (0.53 to 0.90)) and serum levels (receiver operating curve cut-off
value of 260 pg/mL, AUROC 0.68, 95% CI (0.52 to 0.83)) were useful to predict short term
mortality in patients with AH. These results suggest that CCL20 may play a role in the
pathophysiology of AH and could be used as a biomarker to predict short term mortality.
CCL20 proinflammatory and profibrogenic effects on HSCs
As hepatic expression of CCL20 was found to be increased in AH patients with METAVIR
F4 compared with those with METAVIR F1–F3 (figure 2B), and as HSCs are key players in
the development of liver fibrosis in the injured liver, we next investigated the potential of
HSCs to synthesise CCL20 and its biological effects on these cells. We first investigated if
mediators known to play a role in ALD and typically present in the AH microenvironment
induced CCL20 expression in human primary HSCs. Incubation of HSCs with LPS, TNFα
and IL1β induced a marked increase in CCL20 mRNA levels (p<0.05), as shown in figure
3A. On the other hand, to investigate the biological effects of CCL20 on HSCs, cells were
incubated with recombinant CCL20. The chemokine induced the expression of
proinflammatory (MCP1, RANTES, ICAM1) (p<0.05) and profibrogenic (COL1A1, TGFβ)
(p<0.05) genes in HSCs (figure 3B). To investigate if CCL20 had a chemoattractant effect
on HSCs, we performed a migration test using a Boyden chamber. We found increased HSC
migration after cell stimulation with CCL20 (p<0.005) (figure 3C). Previous studies showed
the implication of ERK in HSC migration and activation27 so we tested if CCL20 induced
HSC migration occurred in an ERK dependent manner. Interestingly, CCL20 induced
transient activation of ERK phosphorylation (figure 3D), and preincubation of HSCs with
U0126, a MEK 1/2 specific inhibitor, reduced CCL20 induced migration of HSCs (p=0.014)
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(figure 3E, C). These results indicate that CCL20 exerts proinflammatory and profibrogenic
effects on HSCs and enhances their migration through ERK signalling.
LPS induces hepatic upregulation of CCL20
Our group and others have been working on the development of an animal model of severe
AH but, unfortunately, the existing models do not reproduce the pathophysiology of severe
AH observed in humans. For this reason, and in order to uncover the mechanisms driving
the increase in CCL20 expression in AH and its cellular source, we used different animal
models of liver injury representative of some of the key events that occur in AH, such as
ethanol consumption, fibrosis and endotoxaemia. We first tested the effect of ethanol on
Ccl20 hepatic expression. Mice administered ethanol by gavage did not show increased
Ccl20 hepatic levels (data not shown) while other molecules important in AH, such as Fn14,
were found to be increased in this model,8 suggesting that ethanol itself may not be directly
implicated in the regulation of CCL20. We next investigated if CCl4 administration or LPS
induced Ccl20 hepatic expression. We found that CCl4 and LPS significantly increased
Ccl20 hepatic gene expression (p<0.05) (figure 4A). Importantly, mice treated with a
combination of CCl4 and LPS had a strong increase in Ccl20 hepatic expression compared
with mice treated with LPS, CCl4 and control mice (p<0.05, figure 4A). The extent of liver
damage in mice injected with the combination of CCl4 and LPS was confirmed by multiple
approaches that underlined increased collagen deposition, enhanced hepatic gene expression
of Col1a1, Tgfβ, Icam1, and F4/80, and enhanced protein expression of F4/80, CCL20 and
ICAM1 (figure 4B, C).
Macrophages are the main cell source of hepatic CCL20 in LPS induced liver injury
In order to identify the main cell source of CCL20 in the injured liver, different hepatic cell
populations were isolated from livers of mice subjected to a model of acute-on-chronic liver
injury (CCl4 plus LPS), and Ccl20 expression was assessed. As shown in figure 4D, we
identified macrophages as the hepatic cell type expressing higher levels of Ccl20 (p<0.001),
followed by HSCs, T cells and hepatocytes (p<0.05 for all, compared with whole liver). As
macrophages were identified as the main hepatic Ccl20 cell source, and because their
activation is a crucial step in liver inflammation and fibrosis, we also explored Ccl20
production in vitro in a RAW264 cell line. We found that LPS induced a strong increase in
Ccl20 gene expression in a dose dependent manner in these cells (figure 4E).
Silencing CCL20 ameliorates LPS-induced liver injury
Once LPS was identified as one of the major inducers of Ccl20, we evaluated the effects
mediated by CCL20 in LPS induced liver injury. Mice treated with LPS showed an
important increase in ALT, AST and lactate dehydrogenase (LDH) levels, which were
markedly reduced in animals pretreated with shRNA specific for CCL20 compared with
control shRNA (figure 5A). Moreover, LPS induced an important increase in Ccl20, Nos2,
Icam1, Mcp1, Tgfβ and Col1a1 gene expression. Animals treated with CCL20 shRNA
showed a marked reduction in Ccl20 expression at the mRNA and protein levels, indicating
an efficient knockdown by the shRNA treatment (figure 5B, C). Moreover, we observed a
clear decrease in Nos2, Icam1, Mcp1 and Tgfβ gene expression (p<0.05) in animals treated
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with CCL20 shRNA and LPS. Col1a1 also showed a tendency to decrease (figure 5B). We
also found a reduction in hepatic protein expression of NOS2 and ICAM1 (p<0.05) in mice
injected with CCL20 shRNA and LPS compared with the control group (figure 5C).
Furthermore, CCL20 knockdown reduced macrophages and neutrophil hepatic infiltration
(p<0.05) (figure 5D), and caspase-8 (p=0.059) and caspase-3 (p=0.077) cleavage (figure
5E). These results suggest that CCL20 mediates LPS induced hepatocellular damage,
regulates important genes known to participate in the pathogenesis of AH and modulates the
hepatic inflammatory infiltrate.
DISCUSSION
AH is a form of acute-on-chronic liver damage characterised by hepatocellular damage,
inflammatory infiltrate and fibrosis. There is a clear need to identify key drivers of this
disease to develop new targeted therapies. Here we investigated the potential role of CCL20,
a chemokine that was found to be significantly upregulated in patients with AH. We
performed a translational approach, including hepatic and serum studies and molecular–
clinical correlations, to evaluate the potential role of CCL20 in the pathogenesis of AH.
Because there are no available animal models reproducing all of the features of severe AH,
we used experimental models of acute, chronic and acute-on-chronic liver injury, which
resemble some of the key hallmarks of AH in humans. A new experimental model to induce
severe alcohol liver disease in mice has been described recently,910 but its suitability to
study AH still needs to be confirmed. Our results strongly suggest that CCL20 is not only a
potential biomarker, but also may play a role in the pathogenesis of AH. This conclusion is
based on results showing that CCL20 hepatic and serum levels correlate with disease
severity and in vitro and experimental data showing that CCL20 mediates fibrosis,
inflammation and hepatocellular injury. Obviously, these results needs to be further
confirmed in a larger cohort of patients and, when available, in experimental models of
severe AH.
AH is characterised by an important inflammatory response that mediates the complex
interaction among inflammatory cells, hepatocytes and non-parenchymal cells.5 Here we
showed profound upregulation of CCL20 in patients with AH and its correlation with key
clinical features of the disease and short term mortality, indicating that CCL20 may
represent a good biomarker in patients with AH. Nevertheless, the usefulness of CCL20 to
predict outcome in AH patients needs to be further confirmed in a larger cohort of patients.
Patients with AH commonly show increased gut permeability and bacterial translocation to
the liver, with consequent activation of many hepatic cell types, and activation and
perpetuation of hepatic inflammatory and fibrogenic responses.1328–31 One of the most
striking findings of this study is the strong correlation between circulating CCL20 and LPS
serum levels, suggesting that hepatic CCL20 upregulation may result from increased levels
of circulating pathogen associated molecular patterns that activate macrophages in the
injured liver. Supporting this hypothesis, we identified macrophages and activated HSCs as
the main hepatic Ccl20 cell sources in an experimental model of acute-on-chronic liver
injury where we combined fibrosis and endotoxaemia in order to reproduce two of the main
events that occur in AH. The specific role of LPS in CCL20 induction was further confirmed
in animal models of LPS induced liver damage, where Ccl20 hepatic levels were strongly
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upregulated following LPS administration. These results indicate that increased gut
permeability, that typically occurs in cirrhotic and AH patients, may result in an increased
CCL20 hepatic expression.
In addition to being a potential biomarker, we also suggest a role for CCL20 in the
pathophysiology of AH. CCL20 is well known to mediate recruitment of CCR6 positive
cells during liver injury,25 which are involved in the amplification of the local inflammatory
response.2432–34 Recently, CCR6 has been shown to exert an important role in the
modulation of liver inflammation and fibrosis.24 However, little is known about the direct
effects of CCL20 in the injured liver. Although most of the patients included in our study
were cirrhotic, hepatic expression of CCL20 was significantly higher in patients with
METAVIR F4 compared with those with mild fibrosis (METAVIR F1–F3), suggesting that
CCL20 could be related to fibrogenesis. We provided evidence that CCL20 exerts
proinflammatory and profibrogenic effects in cultured human primary HSCs and enhances
ERK dependent migration in these cells, suggesting a role for this chemokine in the
progression of liver fibrosis.
The main limitation to investigation of the mechanisms driving liver injury in AH patients is
the lack of an appropriate animal model reproducing the key pathophysiological features of
AH. For this reason, we investigated induction of CCL20 expression in animal models of
acute-on-chronic liver injury. Interestingly, ethanol administration did not induce by itself
Ccl20 hepatic expression. On the contrary, when damaged livers were challenged with an
inflammatory insult (LPS), there was strong induction of hepatic Ccl20. Importantly, CCl4
and LPS showed an additive effect, suggesting that endotoxaemia, in the context of liver
fibrosis, may enhance expression of CCL20. This observation suggests that ethanol may not
be the direct trigger of the CCL20 increase and that endotoxaemia may have the
predominant role in the induction of hepatic Ccl20. The most sensitive hepatic cell types to
LPS are macrophages, in which LPS promotes activation, M1 polarisation and the burst of
inflammatory events3536 and HSCs. Macrophages and, to a lesser extent HSCs and other
liver cell types, were found to be the main cell source of Ccl20 both in vitro and in the
acute-on-chronic (CCl4+LPS) liver injury model, suggesting that macrophages and activated
HSCs are the main cell types responsible for the cascade of events from LPS-TLR4
activation to Ccl20 induction and consequent worsening of hepatic inflammation and
fibrosis.
In order to confirm that CCL20 mediates the effects of LPS induced liver injury, we used a
specific shRNA to silence Ccl20 hepatic expression in vivo. Knockdown of Ccl20 reduced
AST, ALT and LDH serum levels, caused a reduction in important hepatic proinflammatory
and profibrogenic genes and proteins, and decreased macrophage and neutrophil hepatic
infiltration. These results provide new important findings in the cascade of events in
response to LPS induced liver damage where CCL20 may play an important role inducing
both direct damage on liver cells and/or participating through an indirect manner in the LPS
cascade that leads to liver injury, hepatic inflammation and fibrosis. The fact that CCL20
regulates expression of other well described molecules involved in the pathogenesis of ALD
such as MCP1183738 and TGFβ1839 is an important finding that allows us to include CCL20
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into the group of the proinflammatory and profibrogenic molecules that participate in the
progression and pathogenesis of AH.
Understanding the role of cytokines in liver disease and their interaction with inflammatory
and resident hepatic cells is of the utmost importance to depict the complex inflammatory
response that takes place during AH and to define new therapeutic strategies. Our study
demonstrates that CCL20 is markedly upregulated in patients with AH and provides
evidence that CCL20 may be an important mediator in LPS induced liver inflammation,
fibrosis, hepatocellular damage and inflammatory cell recruitment, and could be used as a
new biomarker to determine outcome in AH patients. However, further preclinical studies in
future models of AH are required to determine if targeting CCL20 is an effective and safe
therapeutic strategy to modulate the inflammatory response and liver injury in AH.
Moreover, issues regarding CCL20 specificity, modulation of inflammatory cell recruitment
and safety will need special attention to evaluate the potential of CCL20 as a therapeutic
target in patients with AH.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance of this study
What is already known on this subject?
• Alcoholic hepatitis (AH) is the most severe form of alcoholic liver disease
(ALD) and is associated with a high rate of short term mortality. Current
therapies such as corticosteroids are not fully effective, and new targeted
therapies for the treatment of this disease are urgently needed.
• Alcohol consumption leads to an increase in endotoxin levels in the blood. Once
it reaches the liver, endotoxin mostly activates Kupffer cells and hepatic stellate
cells, and determines the promotion and perpetuation of hepatic inflammation
and fibrosis.
• CCL20 is a proinflammatory chemokine strongly induced in different cell types
by lipopolysaccharide (LPS), tumour necrosis factor α and interleukin 1β, and is
known to recruit chemokine receptor 6 positive cells.
What are the new findings?
• CCL20 hepatic expression and serum levels are elevated in patients with AH
and are associated with key clinical features of the disease, such as grade of
fibrosis, portal hypertension severity, endotoxaemia and hepatic neutrophil
infiltration. Increased CCL20 hepatic gene expression and serum levels are
associated with short term mortality in patients with AH.
• Macrophages and hepatic stellate cells are the main CCL20 producing cell types
in experimental acute-on-chronic liver damage induced by the combined
treatment of chronic carbon tetrachloride and LPS.
• CCL20 exerts proinflammatory and profibrogenic effects on primary human
hepatic stellate cells in vitro.
• CCL20 knockdown reduces LPS induced liver damage and causes an important
decrease in proinflammatory and profibrogenic genes.
How might it impact on clinical practice in the foreseeable future?
• The identification of molecular drivers of AH will provide new potential targets
for therapy for this severe disease. In our study, we have provided relevant
results which show a correlation between CCL20 hepatic and serum levels with
grade of fibrosis, portal hypertension, endotoxaemia, neutrophil infiltration and
mortality in patients with AH. These findings represent new interesting
discoveries in the pathophysiology of ALDs and suggest that CCL20 may play
an important role in the pathogenesis of AH. Moreover, the correlation of
CCL20 with patient outcome suggests that CCL20 serum levels could be used as
a biomarker to predict short term mortality in patients with AH.
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CCL20 hepatic and serum levels in patients with alcoholic hepatitis (AH). (A) CCL20
hepatic gene expression in patients with AH (n=32), non-alcoholic steatohepatitis (NASH)
(n=8), HCV (n=8) and compensated cirrhosis (n=8) compared with normal livers (n=8)
(*p<0.005 vs normal livers, **p<0.001 vs normal livers, #p<0.001 vs other groups). (B)
CCL20 serum levels (from peripheral blood) in patients with AH (n=49), HCV (n=8),
compensated cirrhosis (n=15) and healthy controls (n=8) (*p<0.005 vs controls, **p<0.001
vs controls, #p<0.001 vs other groups). (C) Correlation between CCL20 hepatic gene
expression and CCL20 serum levels in patients with AH (n=32) (p=0.03).
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CCL20 expression and correlation with clinical features of alcoholic hepatitis (AH). (A)
Correlation between CCL20 hepatic gene expression and Model for End-stage Liver Disease
(MELD) score in patients with AH (n=32) (p<0.0001). (B) CCL20 hepatic gene expression
in patients with AH and METAVIR F4 (patients with cirrhosis, n=27) and METAVIR F1–3
(patients without cirrhosis, n=5) (p=0.01). (C) Comparison of CCL20 hepatic gene
expression and the severity of portal hypertension in patients with AH (severe portal
hypertension (hepatic venous pressure gradient (HVPG)>20 mm Hg) n=12 and non-severe
portal hypertension (HVPG<20 mm Hg) n=20; p=0.008). (D) Correlation between CCL20
and lipopolysaccharide (LPS) serum levels in patients with AH (n=49) (p<0.0001). (E)
Kaplan–Meier curve showing 90 day mortality according to CCL20 hepatic gene expression.
A value of 80-fold expression (2−ΔΔCt) was identified as the cut-off value with best
sensitivity and specificity to define patients with low (≤80-fold) and high (>80-fold) CCL20
gene expression (p=0.01). (F) Kaplan–Meier curve showing 90 day mortality according to
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CCL20 serum levels in patients with AH. A value of 260 pg/mL was identified as the cut-off
with better sensitivity and specificity to define patients with low (≤260 pg/mL) or high
(>260 pg/mL) circulating CCL20 serum levels (p=0.03).
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CCL20 production in hepatic stellate cells (HSCs) and CCL20 effects on HSCs. (A) CCL20
gene expression in HSCs incubated with lipopolysaccharide (LPS) 1 μg/mL, tumour
necrosis factor α (TNFα) 1 ng/mL and interleukin 1β (IL-1β) 20 ng/mL for 24 h. (B) HSCs
were incubated with CCL20 250 ng/mL and 1 μg/mL for 24 and 48 h, respectively. mRNA
expression was determined by quantitative real time PCR and was expressed as fold versus
basal (*p<0.05 compared with basal). (C) Effects of CCL20 on HSC migration were
evaluated using a Boyden chamber. Both CCL20 250 ng/mL and platelet derived growth
factor (PDGF) 20 ng/mL (used as a positive control) increased HSC migration, expressed as
mean of migrated cells with respect to controls (*p<0.005). Representative pictures of
Giemsa positive migrated cells (×400 magnification) are also shown for control, CCL20 250
ng/mL and PDGF 20 ng/mL stimulated cells in the presence or absence of 10 μM U0126, a
specific MEK1/2 inhibitor. (D) Representative western blot of time course stimulation of
HSCs with CCL20 250 ng/mL. CCL20 induced a transient extracellular signal regulated
kinase (ERK) phosphorylation. (E) Quantification of the number of migrated HSCs
incubated with CCL20 250 ng/mL in the presence or absence of U0126 10 μM (*p<0.005 vs
vehicle; **p=0.014 vs CCL20 stimulated cells).
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Ccl20 hepatic expression in animal models of liver injury and CCL20 cell source. (A)
Hepatic Ccl20 gene expression in mice treated with carbon tetrachloride (CCl4) (n=6),
lipopolysaccharide (LPS) (n=6) and CCl4 plus LPS (n=12) (see online supplementary
material) (*p<0.05 compared with controls; **p<0.05 compared with control and other
groups). (B) Representative images of sirius red staining in the liver of (i) control (×200
magnification) and (ii) CCl4 plus LPS treated mice (×200 magnification), and representative
images of F4/80 and CCL20 immunohistochemistry in the liver of (i) control and (ii) CCl4
plus LPS treated mice (×200 magnification). (C) Hepatic Col1a1, Tgfβ, F4/80 and Icam1
gene expression in mice administered CCl4 plus LPS (*p<0.05) and representative western
blot of hepatic ICAM1 protein expression and quantification in mice treated with CCl4 plus
LPS compared with the control group (*p<0.05). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an endogenous control. (D) Ccl20 mRNA levels in
vitamin A+ HSCs (VitA+), neutrophils (Ly6G+), hepatocytes (Hep), T cells (CD3+), total
HSCs (HSCs) and macrophages (F4/80+) isolated from the liver of mice administered CCl4
plus LPS (*p<0.05 compared with controls, **p<0.01 compared with other cell types); as a
control to normalise the results, we used whole liver samples from mice treated with CCl4
plus LPS. (E) Ccl20 gene expression in RAW264 cells incubated with LPS 10 ng/mL, 100
ng/mL and 1 μg/mL for 24 h (*p<0.05).
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CCL20 mediates lipopolysaccharide (LPS) induced liver damage. (A) Aspartate
aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH)
serum levels in mice treated with control short hairpin interference inducing construct
(shRNA) (shCtrl) (n=6) or CCL20 shRNA (shCCL20) (n=6) and LPS (see online
supplementary material) (*p<0.05 compared with vehicle; **p<0.05 compared with control
shRNA). (B) Hepatic Ccl20, Nos2, Icam1, Mcp1, Tgfβ and Col1a1 gene expression in mice
treated with control shRNA (n=6) or CCL20 shRNA (n=6) and LPS (*p<0.05 compared
with vehicle; **p<0.05 compared with control shRNA). (C) Representative western blot and
quantification of hepatic CCL20 and representative pictures of CCL20
immunohistochemistry in the liver of mice injected with (i) control shRNA and LPS and (ii)
CCL20 shRNA and LPS. Representative western blots and protein expression quantification
of NOS2 and ICAM1 in the liver of mice treated with control shRNA or CCL20 shRNA and
LPS. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous
control (*p<0.05 compared with control shRNA). (D) Representative F4/80 and
myeloperoxidase (MPO) immunostainings of liver sections of control shRNA or CCL20
shRNA and LPS treatment (×200 magnification). Quantification of positive stained areas is
shown in the graphs (*p<0.05 compared with control shRNA). (E) Representative western
blots of total and cleaved caspase-8 and caspase-3 in the liver of mice treated with control
shRNA or CCL20 shRNA and LPS. Caspase cleavage is represented as the ratio of cleaved
caspase versus total caspase compared with the control group.
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Table 1
Baseline demographic and clinical parameters of patients with alcoholic hepatitis (n=49)
Characteristic Median (25–75 IQR) or n (%)
Age (years) 52 (47–56)
Male (n (%)) 39 (80)
Alcohol intake (g/day) 100 (80–160)
Corticosteroids (n (%)) 25 (51)
Laboratory and hemodynamic parameters
 Haemoglobin (g/dL) 11 (10–13)
 Leucocyte count (×109/L) 8.4 (6.3–12.5)
 Platelet count (×109/L) 113 (77–201)
 AST (U/L) 117 (67–157)
 ALT (U/L) 37 (25–60)
 Serum Na (mmol/L) 135 (132–139)
 Serum albumin (g/dL) 2.6 (2.3–3.2)
 Serum creatinine (mg/dL) 0.9 (0.60–1.1)
 Serum bilirubin (mg/dL) 6.7 (3.0–18.7)
 International normalised ratio 1.6 (1.4–1.8)
 HVPG (mm Hg) 19 (15–22)
Alcoholic hepatitis severity scores at admission
 MELD score 19 (14–24)
 ABIC score 7.8 (6.7–8.6)
ABIC class (n (%))
 A (<6.71) 11 (23)
 B (6.71–8.99) 30 (61)
 C (≥9) 8 (16)
Clinical decompensations during hospitalisation
 AKI (n (%)) 20 (41)
 Infection (n (%)) 21 (43)
 Mortality at 90 days (n (%)) 14 (29)
ABIC, Age-Bilirubin-INR-Creatinine score; AKI, acute kidney injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HVPG,
hepatic venous pressure gradient; MELD, Model for End-stage Liver Disease.
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